Food and healthtech company Lykon has successfully raised €2.5 million in its latest funding round, led by existing investor Zintinus Fund I. The company aims to be a market leader in personalised nutrition programs and products, utilising certified blood and DNA tests, motivational psychology concepts, and artificial intelligence (AI).
With its science-based approach, Lykon has already helped over 150,000 individuals achieve their health goals. Recently, the company has focused on sustainable weight management as a key area of interest. Its ultimate goal is to assist one million people in achieving a healthy weight and avoiding associated health issues like diabetes type 2 and depression.
Personalised nutrition as a way to combat obesity
Unfortunately, the obesity epidemic is a significant concern in Europe, with 59% of Europeans classified as overweight and 24% suffering from obesity, according to the World Health Organisation (WHO). Lykon’s new funding will enable the company to develop innovative products and services to combat this crisis and promote sustainable weight loss.
Lykon CEO Tobias Teuber expressed his pride in securing the financing round, given the challenging economic climate. The continued support from both existing and new investors demonstrates confidence in Lykon’s vision and proves the effectiveness of the brand.
Just last year, Lykon raised €10 million in a Series A funding round, also led by Zintinus Fund I. The company has been at the forefront of developing personalised nutrition concepts since its founding in 2018. By combining medical research, laboratory-diagnostic blood and DNA analyses, psychological components, and AI, Lykon empowers individuals to make healthy and sustainable behavioral changes, taking control of their own health.
Also read Heartfulness Institute to set up a one-of-its-kind Millet Experience Centre
